| scholarly article | Q13442814 |
| P50 | author | Robin Murray | Q7352679 |
| Daniel Stahl | Q37369733 | ||
| Paul Allen | Q37834596 | ||
| Philip McGuire | Q37834611 | ||
| Federico Turkheimer | Q41330642 | ||
| Oliver Howes | Q42551337 | ||
| Lucia Valmaggia | Q42823642 | ||
| P2093 | author name string | S Bose | |
| A Egerton | |||
| I Valli | |||
| P2860 | cites work | The dopamine hypothesis of schizophrenia: version III--the final common pathway | Q22242827 |
| Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis | Q28237307 | ||
| Deconstructing psychosis with human brain imaging | Q31114592 | ||
| Increased dopamine transmission in schizophrenia: relationship to illness phases | Q33679807 | ||
| Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms | Q34153146 | ||
| Presynaptic regulation of dopamine transmission in schizophrenia | Q34415890 | ||
| Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States | Q34475129 | ||
| Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America | Q34586836 | ||
| The role of dopamine for the pathophysiology of schizophrenia | Q34658860 | ||
| Molecular brain imaging and the neurobiology and genetics of schizophrenia | Q35608262 | ||
| Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. | Q36941951 | ||
| Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis | Q37022940 | ||
| Elevated striatal dopamine function linked to prodromal signs of schizophrenia | Q46174418 | ||
| Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis | Q55969864 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | psychosis | Q170082 |
| striatum | Q1319792 | ||
| P304 | page(s) | 885-886 | |
| P577 | publication date | 2011-03-01 | |
| P1433 | published in | Molecular Psychiatry | Q6895973 |
| P1476 | title | Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study | |
| P478 | volume | 16 |
| Q90752929 | 'At risk mental state' clinics for psychosis - an idea whose time has come - and gone! |
| Q50096180 | A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia |
| Q99604509 | A potential biomarker for treatment stratification in psychosis: evaluation of an [18F] FDOPA PET imaging approach |
| Q37381202 | Adolescent behavior and dopamine availability are uniquely sensitive to dietary omega-3 fatty acid deficiency |
| Q37489007 | Adversity in childhood linked to elevated striatal dopamine function in adulthood |
| Q37019129 | Altered dopamine ontogeny in the developmentally vitamin D deficient rat and its relevance to schizophrenia |
| Q38759421 | Altering the course of schizophrenia: progress and perspectives |
| Q33839379 | An Integrative Perspective on the Role of Dopamine in Schizophrenia |
| Q26991569 | An Overview of the Association between Schizotypy and Dopamine |
| Q91236277 | An integrative framework for perceptual disturbances in psychosis |
| Q38084211 | Antipsychotic interventions in prodromal psychosis: safety issues |
| Q47641624 | Auditory hallucinations, not necessarily a hallmark of psychotic disorder. |
| Q33866125 | Classics in Chemical Neuroscience: Aripiprazole. |
| Q35182103 | Cognitive control of gaze in bipolar disorder and schizophrenia. |
| Q40944292 | Contribution of non-genetic factors to dopamine and serotonin receptor availability in the adult human brain |
| Q50420782 | Core beliefs in healthy youth and youth at ultra high-risk for psychosis: Dimensionality and links to depression, anxiety, and attenuated psychotic symptoms |
| Q42650189 | Cross-Cutting Advancements Usher in a New Era for Motor Research in Psychosis |
| Q50192659 | Defining the Locus of Dopaminergic Dysfunction in Schizophrenia: A Meta-analysis and Test of the Mesolimbic Hypothesis |
| Q35096522 | Detecting the psychosis prodrome across high-risk populations using neuroanatomical biomarkers |
| Q52573337 | Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study. |
| Q47895125 | Developmental timing and critical windows for the treatment of psychiatric disorders. |
| Q36636329 | Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task |
| Q42544638 | Dopamine and the aberrant salience hypothesis of schizophrenia |
| Q99418608 | Dopamine dysregulation in psychotic relapse after antipsychotic discontinuation: an [18F]DOPA and [11C]raclopride PET study in first-episode psychosis |
| Q97093691 | Dopamine manipulations modulate paranoid social inferences in healthy people |
| Q36928703 | Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study |
| Q47550545 | Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. |
| Q36939999 | Dopaminergic function in the psychosis spectrum: an [18F]-DOPA imaging study in healthy individuals with auditory hallucinations |
| Q37331631 | Early detection and intervention in bipolar affective disorder: targeting the development of the disorder |
| Q57403237 | Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis |
| Q39037300 | Elevated Striatal Dopamine Function in Immigrants and Their Children: A Risk Mechanism for Psychosis. |
| Q64104363 | Enhanced Dopamine in Prodromal Schizophrenia (EDiPS): a new animal model of relevance to schizophrenia |
| Q30413207 | Epigenetic reprogramming of cortical neurons through alteration of dopaminergic circuits. |
| Q37975281 | Ethical implications for clinical practice and future research in "at risk" individuals. |
| Q35369662 | Evidence that environmental and genetic risks for psychotic disorder may operate by impacting on connections between core symptoms of perceptual alteration and delusional ideation |
| Q36872150 | From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments |
| Q36992322 | Glutamate and dopamine in schizophrenia: an update for the 21st century |
| Q90748306 | Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study |
| Q28087255 | How Schizophrenia Develops: Cognitive and Brain Mechanisms Underlying Onset of Psychosis |
| Q35610726 | How can neuroimaging facilitate the diagnosis and stratification of patients with psychosis? |
| Q101403283 | Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [11C]-(+)-PHNO PET with methylphenidate challenge study |
| Q37666517 | Impacts of stress and sex hormones on dopamine neurotransmission in the adolescent brain |
| Q47357393 | Increased Striatal and Reduced Prefrontal Cerebral Blood Flow in Clinical High Risk for Psychosis |
| Q59784320 | Increased resting perfusion of the hippocampus in high positive schizotypy: A pseudocontinuous arterial spin labeling study |
| Q34703195 | Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials |
| Q37979672 | Is clinical intervention in the ultra high risk phase effective? |
| Q37015339 | Is neuroimaging clinically useful in subjects at high risk for psychosis? |
| Q37563725 | Longitudinal alterations in motivational salience processing in ultra-high-risk subjects for psychosis. |
| Q38650161 | Mapping the Consequences of Impaired Synaptic Plasticity in Schizophrenia through Development: An Integrative Model for Diverse Clinical Features |
| Q37256211 | Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study |
| Q91931406 | Models of persecutory delusions: a mechanistic insight into the early stages of psychosis |
| Q37262953 | Molecular imaging as a guide for the treatment of central nervous system disorders |
| Q47836636 | Motion energy analysis reveals altered body movement in youth at risk for psychosis |
| Q37228333 | Neural and behavioral correlates of aberrant salience in individuals at risk for psychosis |
| Q36408037 | Neural signals encoding shifts in beliefs |
| Q36386404 | Neuroanatomical maps of psychosis onset: voxel-wise meta-analysis of antipsychotic-naive VBM studies |
| Q34552937 | Neuroimaging findings in the at-risk mental state: a review of recent literature |
| Q93023762 | Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis |
| Q38119411 | Novel nutritional treatment for manic and psychotic disorders: a review of tryptophan and tyrosine depletion studies and the potential of protein-based formulations using glycomacropeptide |
| Q36914587 | Partial volume correction using structural-functional synergistic resolution recovery: comparison with geometric transfer matrix method |
| Q34527656 | Pathway-Specific Dopamine Abnormalities in Schizophrenia |
| Q41850803 | Patients with schizophrenia show aberrant patterns of basal ganglia activation: Evidence from ALE meta-analysis |
| Q50025633 | Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis |
| Q48219402 | Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study |
| Q38219577 | Presynaptic dopaminergic function: implications for understanding treatment response in psychosis |
| Q99203576 | Prevention of psychosis: moving on from the at-risk mental state to universal primary prevention |
| Q33942094 | Recent advances in understanding schizophrenia |
| Q36850586 | Reduced presynaptic dopamine activity in adolescent dorsal striatum |
| Q94550971 | Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine |
| Q39051914 | Research domain criteria (RDoC) grows up: Strengthening neurodevelopment investigation within the RDoC framework |
| Q35591134 | Role of nitric oxide and related molecules in schizophrenia pathogenesis: biochemical, genetic and clinical aspects. |
| Q64085157 | Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms |
| Q34023115 | Schizophrenia: an integrated sociodevelopmental-cognitive model |
| Q34023184 | Spatial working memory ability in individuals at ultra high risk for psychosis |
| Q89487559 | Stem Cells for Improving the Treatment of Neurodevelopmental Disorders |
| Q57403286 | Striatal dopamine synthesis capacity in twins discordant for schizophrenia |
| Q38805970 | Striatal dopamine, reward, and decision making in schizophrenia |
| Q37425054 | The 3rd Schizophrenia International Research Society Conference, 14-18 April 2012, Florence, Italy: summaries of oral sessions |
| Q57715244 | The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study |
| Q38976291 | The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia |
| Q57463081 | The effect of the DISC1 Ser704Cys polymorphism on striatal dopamine synthesis capacity: an [18F]-DOPA PET study |
| Q46296210 | The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders |
| Q97556098 | The mGluR2/3 agonist pomaglumetad methionil normalizes aberrant dopamine neuron activity via action in the ventral hippocampus |
| Q37062793 | The nature of dopamine dysfunction in schizophrenia and what this means for treatment |
| Q38232366 | The neurobiology and treatment of first-episode schizophrenia |
| Q42907698 | The neuromodulator of exploration: A unifying theory of the role of dopamine in personality |
| Q43922950 | The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory : A dual [(11)C]raclopride and [(18) F]FDG imaging study with aripiprazole |
| Q91130303 | The relationship between grey matter volume and striatal dopamine function in psychosis: a multimodal 18F-DOPA PET and voxel-based morphometry study |
| Q96952371 | The role of dopamine dysregulation and evidence for the transdiagnostic nature of elevated dopamine synthesis in psychosis: a positron emission tomography (PET) study comparing schizophrenia, delusional disorder, and other psychotic disorders |
| Q27026637 | The role of α5 GABAA receptor agonists in the treatment of cognitive deficits in schizophrenia |
| Q38260578 | Towards indicated prevention of psychosis: using probabilistic assessments of transition risk in psychosis prodrome |
| Q30447851 | Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals |
| Q26860217 | Translating the MAM model of psychosis to humans |
| Q38249908 | What causes aberrant salience in schizophrenia? A role for impaired short-term habituation and the GRIA1 (GluA1) AMPA receptor subunit. |
| Q45958384 | [Personalised medicine in psychiatry and psychotherapy. A review of the current state-of-the-art in the biomarker-based early recognition of psychoses]. |
| Q86636393 | [Should antipsychotics be used in prodromal stages of schizophrenia to prevent psychosis? Pro] |
Search more.